相关实验视频

Updated: Jul 3, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

在DAA失败后的患者中,voxilaprevir/velpatasvir/sofosbuvir的实际有效性

Christiana Graf¹, Roberta D'Ambrosio², Elisabetta Degasperi²

¹Department of Internal Medicine 1, University Hospital, Goethe University, Frankfurt, Germany.

JHEP reports : innovation in hepatology

|February 15, 2024

概括

沃克西拉普雷维尔/韦尔帕塔斯维尔/索福斯布维尔 (VOX/VEL/SOF) 重复治疗对慢性肝炎C病毒 (HCV) 感染有效,达到95%的持续病毒学反应. 然而,HCV3基因型,肝癌和肝硬化独立预测治疗失败.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
临床医学临床医学

背景情况:

患有慢性型肝炎病毒 (HCV) 感染的经验丰富的直接作用抗病毒 (DAA) 患者往往需要重新治疗.
沃克西拉普雷维尔/韦尔帕塔斯维尔/索福斯布维尔 (VOX/VEL/SOF) 是一种高效的再治疗选择.

研究的目的:

分析DAA经验丰富的患者对VOX/VEL/SOF病毒学反应的治疗有效性和预测因素.
在现实世界的队列中识别影响治疗结果的因素.

主要方法:

进行了对三大现实世界队伍的综合分析.
在2016年至2021年期间,重新接受VOX/VEL/SOF治疗的746名DAA患者被纳入.
分析了病毒学治疗反应的预测因素.

主要成果:

总的来说,95.4%的患者实现了持续的病毒学反应 (SVR).
肝细胞癌,肝硬化和HCV基因型3是治疗失败的独立预测因素.
与耐药性相关的替代物没有影响治疗结果.

结论:

在经历过DAA的患者中,VOX/VEL/SOF重复治疗显示出高效.
3型HCV基因型,肝癌和肝硬化是治疗失败的关键因素.
需要进一步的研究来优化难以治疗的患者的再治疗策略.

关键词:

在DAA治疗失败后,治疗失败了.肝炎C病毒感染者重新处理再处理沃克西拉普雷维尔/韦尔帕塔斯维尔/索福斯布维尔

更多相关视频

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors

Published on: September 13, 2018

相关概念视频

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...